The estimated Net Worth of Stephen A Hill is at least $54.4 Tausend dollars as of 16 December 2020. Stephen Hill owns over 7,500 units of Lipocine Inc stock worth over $49,980 and over the last 21 years he sold LPCN stock worth over $4,385. In addition, he makes $0 as Lead Independent Director at Lipocine Inc.
Stephen has made over 10 trades of the Lipocine Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of LPCN stock worth $29,400 on 16 December 2020.
The largest trade he's ever made was buying 18,000 units of Lipocine Inc stock on 4 June 2020 worth over $19,440. On average, Stephen trades about 1,467 units every 58 days since 2004. As of 16 December 2020 he still owns at least 12,750 units of Lipocine Inc stock.
You can see the complete history of Stephen Hill stock trades at the bottom of the page.
Dr. Stephen Anthony Hill, M.D., is Lead Independent Director of the Lipocine Inc. Dr. Hill has significant executive management experience in the therapeutics industry. Dr. Hill currently serves as a director, President and Chief Executive Officer of Targacept Inc. (TRGT). He has over 20 years of industry experience, having served previously as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., where he led an organization of over 1,200 employees until its acquisition by Abbott Laboratories in 2010, and ArQule, Inc., where he led a successful transition for the company from a fee-for-service discovery chemistry operation to a company with a proprietary clinical-stage pipeline. Prior to ArQule, Dr. Hill held several leadership positions with F. Hoffmann-La Roche Ltd., including global head of clinical development. He is a Fellow of the Royal College of Surgeons of England and holds degrees in medicine and surgery from St. Catherine’s College at Oxford University.
Stephen Hill is 62, he's been the Lead Independent Director of Lipocine Inc since 2014. There are 3 older and 9 younger executives at Lipocine Inc. The oldest executive at Lipocine Inc is Dr. Mahesh V. Patel Ph.D., 64, who is the Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO.
Stephen's mailing address filed with the SEC is C/O 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT, 84108.
Over the last 11 years, insiders at Lipocine Inc have traded over $9,045 worth of Lipocine Inc stock and bought 890,945 units worth $696,169 . The most active insiders traders include Mahesh V. Patel, John W. Higuchi und Morgan R Brown. On average, Lipocine Inc executives and independent directors trade stock every 72 days with the average trade being worth of $148,846. The most recent stock trade was executed by Mahesh V. Patel on 25 May 2023, trading 8,706 units of LPCN stock currently worth $43,791.
lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.
Lipocine Inc executives and other stock owners filed with the SEC include: